RLMD Research and Charts

RLMD - Relmada Therapeutics Inc (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2025-09-12)

Last 1.59	Change ⇑ +0.07 (+4.61%)	Volume 425,453
	Open 1.52	High 1.60	Low 1.46

8EMA (Daily) 1.40	40EMA (Daily) 0.91	50EMA (Daily) 0.85	STO (Daily) 81.565	MACD Hist (Daily) 0.150
8EMA (Weekly) 1.050	40EMA (Weekly) 1.03	50EMA (Weekly) 1.23	STO (Weekly) 70.027	MACD Hist (Weekly) 0.297


Company Profile
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.